A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34182
Abstract: Patients with refractory central nervous system leukemia (CNSL) have a dismal prognosis and lack effective therapy. Case reports have shown that sorafenib is effective against brain metastases, including leukemia. read more here.
Keywords: system leukemia; central nervous; refractory central; phase study ... See more keywords
A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors
Sign Up to like & getrecommendations! Published in 2022 at "Child's Nervous System"
DOI: 10.1007/s00381-022-05479-7
Abstract: Children with relapsed/refractory central nervous system (CNS) tumors require novel combinations of therapies. Irinotecan and temozolomide (IT) is a frequently used therapy with an established toxicity profile. Bevacizumab is an anti-VEGF monoclonal antibody with demonstrated… read more here.
Keywords: cns tumors; refractory central; central nervous; bevacizumab ... See more keywords
The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/2900310
Abstract: Objective The objective is to explore the effectiveness and safety of CAR T-cell therapy in advanced relapsed/refractory central nervous system B-cell lymphoma and compare the impact of autologous stem cell transplantation (ASCT) plus CAR T-cell… read more here.
Keywords: cell; cell lymphoma; relapsed refractory; cell therapy ... See more keywords